Investigators reported early promise from a Phase 1/2a trial of demethylation-primed tandem CD19/CD20 CAR T cells in relapsed or refractory B-cell lymphomas. The approach combines epigenetic modulation with dual-target CAR T therapy, with the reported results supporting continued development of in-trial immune engineering designed to improve efficacy in hard-to-treat lymphoma settings.